Heterocyclic Compounds

Matches 701 - 750 out of 36,810	< 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 >

Document	Document Title
WO/2023/151640A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the structure (I), wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
WO/2023/151642A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure, wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
WO/2022/268052A9	(R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE Disclosed herein are compounds for binding and modulating the activity of cereblon (CRBN), and methods of use. The present invention also provides compounds that can be used as synthetic intermediates in the preparation of bifunctional c...
WO/2023/151069A1	PYRROLO[2,3-D]SIX-MEMBERED HETEROAROMATIC RING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF A pyrrolo[2,3-d]six-membered heteroaromatic ring derivative of general formula (I), which derivative has an inhibitory activity on Janus kinase (JAK), in particular, has a selective and relatively high inhibitory activity on JAK3 kinase,...
WO/2023/150867A1	COMPOUNDS FOR LABELLING NUCLEIC ACID AND USES THEREOF Theranostic compounds are provided having formula: (Ia), (Ib), or (Ic), or a salt thereof.
WO/2023/151560A1	BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Provided are bicyclic heteroaryl compounds of Formula (I), methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating cancer and other diseases.
WO/2023/154905A1	ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS The disclosure provides compounds of Formulae (I) or (II), or a pharmaceutically acceptable salt thereof, (I), or (II) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compoun...
WO/2023/151636A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
WO/2023/154962A1	CGAS INHIBITORS AND USES THEREOF The disclosure relates generally novel inhibitors of human cGAS and methods of treating cGAS -related diseases or disorders in a patient.
WO/2023/151513A1	CONJUGATES OF CHEMOTHERAPY AGENTS AND TISSUE-BINDING SMALL MOLECULES, COMPOSITIONS AND METHODS THEREOF The invention provides novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, and their use in and methods of treatment of certain diseases or conditions (e.g., cancer).
WO/2023/153748A1	SOS1 INHIBITOR AND DERIVATIVE THEREOF The present invention relates to an SOS1 inhibitor and a derivative thereof. A compound, or a pharmaceutically acceptable salt, hydrate, solvate, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof of the present in...
WO/2023/152042A1	ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, substituted in the 6-position by an arylphenyl or heteroarylphenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in h...
WO/2023/154282A1	COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS Provided herein are compounds and compositions thereof that may be capable of disrupting, interrupting, and/or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provide...
WO/2023/151641A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure, wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
WO/2023/151621A1	COMPOUND HAVING ANTI-KRAS MUTANT TUMOR ACTIVITY The present invention provides compounds capable of being used as KRAS inhibitors and having a structure of formula (A), a pharmaceutical composition comprising such compounds, a method for preparing such compounds, and a use of the comp...
WO/2023/154519A1	INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
WO/2023/154314A1	SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
WO/2023/150186A1	DGK TARGETING COMPOUNDS AND USES THEREOF Disclosed herein are compounds of Formula (A), or a pharmaceutically acceptable salt thereof, which inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα). These compounds are useful in the treatment of proliferative ...
WO/2023/150526A1	COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 Arylsulfonamides of 5-substituted octahydrocyclopenta[c]pyrroles, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatr...
WO/2023/148129A1	IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE The present invention relates to compounds of formula (Ia), (Ia), wherein R2, M1, M2, M3, Q1 and Q2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of usin...
WO/2022/178540A9	TOPICAL FORMULATIONS OF A JAK 1/3 INHIBITOR AND METHODS OF USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS AND OTHER SKIN CONDITIONS The present disclosure relates methods for treating skin disorders caused by an immune deficiency with topical formulations comprising ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2, 3-b]pyridine-5-carboxylate (Compoun...
WO/2023/148501A1	HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
WO/2023/150525A1	COMPETITIVE AND NONCOMPETITIVE PIPERIDINE SULFONYL INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 Arylsulfonamides of 4-substituted-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such a...
WO/2023/148368A1	PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
WO/2023/150540A1	HYDROXAMIC ACID MACROCYCLIC AGENTS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF The invention provides metal chelating agents and metal complexes of these agents of use in therapeutic and diagnostic applications.
WO/2023/150681A1	INHIBITORS OF RAF KINASES Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
WO/2023/150793A1	INHIBITORS OF MALIC ENZYME 1 The present disclosure relates to compounds that inhibit malic enzyme 1. The disclosure further relates to methods of treating cancers mediated by malic enzyme 1.
WO/2023/148369A1	PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
WO/2023/150601A2	MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain ...
WO/2023/150203A1	HDAC6 INHIBITORS AND USES THEREOF Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the...
WO/2023/143147A1	PYRIDAZOPYRIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Provided in the present invention are pyridazopyridone compounds, a pharmaceutical composition thereof, and the use thereof. Specifically, the compounds have structures as shown in formula (I). The compounds can interfere with the intera...
WO/2023/143249A1	PROTEIN DEGRADATION COMPOUND TARGETING MALT1 Disclosed in the present invention are a compound that inhibits MALT1 and promotes the degradation of MALT1 by means of recruiting E3 ubiquitin ligase, and the use of the compound in the preparation of a drug for treating related disease...
WO/2023/142128A1	METHOD FOR SYNTHESIZING 2-PHENYL-5-BENZYL-IMIDAZO[1,2-A]PYRIDINE COMPOUND Disclosed in the present invention is a method for synthesizing a 2-phenyl-5-benzyl-imidazo[1,2-a]pyridine compound. By using a compounded nickel (II) complex having the molecular formula of Ni[P(OEt)3]{[RNC(CH3)C(CH3)NR]C}Br2 (R being 2...
WO/2023/147344A1	ISOCITRATE DEHYDROGENASE 1 INHIBITORS AND METHODS OF USE THEREOF The present disclosure provides compounds of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of inhibiting isocitrate dehydrogenase 1 (ID...
WO/2023/143344A1	NOVEL EGFR INHIBITOR Disclosed is a novel EGFR inhibitor. Specifically, the present invention relates to a compound represented by general formula (1) and a preparation method therefor, as well as a use of the compound represented by general formula (1) and ...
WO/2023/146957A1	PARP1 INHIBITORS AND USES THEREOF Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
WO/2023/143501A1	WNT PATHWAY INHIBITOR COMPOUND Provided are a compound possessing the structure of formula (I) and having excellent Wnt pathway inhibitory activity, or a pharmaceutically acceptable salt, an isotope derivative, or a stereoisomer thereof. Further provided are a prepara...
WO/2023/143282A1	HYDRAZINO GROUP-CONTAINING COMPOUND The present application relates to the field of pharmaceutical chemistry, provides a hydrazino group-containing compound, specifically relates to a compound of formula (I-A), a pharmaceutically acceptable salt thereof, a pharmaceutical c...
WO/2023/145804A1	NOVEL B0AT1 INHIBITOR The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
WO/2023/143352A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, and a use thereof. Provided is a nitrogen-containing heterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a s...
WO/2023/142857A1	PREPARATION METHOD FOR RIMEGEPANT Disclosed in the present invention is a preparation method of Rimegepant. Specifically, the preparation method comprises the following steps: 1) reacting a compound of formula (III) with a compound of formula (IV) in a solvent 1, in the ...
WO/2023/143514A1	PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to a propylene ketone-containing bioinhibitor, a preparation method therefor, and a use thereof. In particular, the present invention relates to the compound represented by each of the general formulas or a ...
WO/2023/143356A1	METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER Disclosed are a methionine adenosyltransferase (MAT) 2A inhibitor represented by formula (I), a preparation method for the inhibitor, a pharmaceutical composition comprising same, and a medical use thereof. The compound has excellent MAT...
WO/2023/143589A1	CEREBLON E3 UBIQUITIN LIGASE INHIBITOR The present invention relates to a compound represented by formula (I), or an isomer, isotope derivative, polymorph, prodrug thereof, or a pharmaceutically acceptable salt or solvate thereof: wherein R1, R2, R3a, R3b, R3c, R3d, W1, W2, G...
WO/2023/143236A1	2H-INDAZOLE-7-FORMAMIDE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION Disclosed are a 2H-indazole-7-formamide compound, a preparation method, a pharmaceutical composition, and an application. The structure of the compound is represented by formula (I), and comprises an isomer or pharmaceutically acceptable...
WO/2023/141866A1	PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE The present invention comprises compounds of Formula (I). Wherein: R 1, R 2, R 3, R 4 and R 5 are defined in the specification, and methods of treating or ameliorating a syndrome, disorder or disease described herein by administration of...
WO/2023/143520A1	ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF Described herein are ENPP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with ENPP1.
WO/2023/143576A1	CRYSTALLINE FORM OR AMORPHOUS FORM OF MACROCYCLIC COMPOUND OR SALT OR SOLVATE THEREOF Disclosed are a crystalline form or an amorphous form of a macrocyclic compound or a salt or solvate thereof, as well as a preparation method therefor and an application thereof. The structure of the macrocyclic compound is represented b...
WO/2023/144793A1	POL THETA INHIBITORS The present invention relates to compounds of formula (I), that possess DNA polymerase theta (POLQ) enzyme inhibitory activity, methods for their preparation, pharmaceutical compositions containing them, and their use in the treatment or...
WO/2023/146990A1	COMPOUNDS AND METHODS OF USE Provided are compounds of Formula (A) and Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ring A, RB, Ring B, R1, R2 and n ...

Matches 701 - 750 out of 36,810	< 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 >